Skip to main content
OpenTrials
Completed

NCT Number: NCT03356561

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of Ad26.ZIKV.001 at 2 dose levels, 5*10^10 viral particles (vp) and 1*10^11 vp, administered intramuscularly as single dose and as 2-dose schedules in healthy adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Johnson County Clinical Trials, Lenexa, Kansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be healthy, without significant medical illness, on the basis of physical examination, medical history, and vital signs performed at screening
  • Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the laboratory normal reference ranges, and additionally within the limits representing Food and Drug Administration (FDA) toxicity Grade 1, the participant may be considered eligible only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Participant must agree not to donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after the last study vaccine administration
  • Participant must be willing to provide verifiable identification
  • All female participants of childbearing potential must have:
  • a negative serum beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening
  • a negative urine (beta-hCG) pregnancy test immediately prior to each study vaccine administration

Exclusion criteria

  • Participant has a known history of flavivirus infection or previous receipt of flavivirus vaccine such as dengue virus (DENV) types 1-4, yellow fever virus (YFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV)
  • Participant has traveled to an area with active flavivirus transmission (as per Centers for Disease Control and Prevention [CDC]'s 'Zika travel notices') or Zika cautionary areas ('Yellow and Red areas') within 4 weeks before screening
  • Participant has chronic active hepatitis B or hepatitis C virus infection, verified at screening by hepatitis B surface antigen (HBsAg) or hepatitis C antibody, respectively
  • Participant has human immunodeficiency virus (HIV) type 1 or type 2 infection
  • Participant received or plans to receive licensed live-attenuated vaccines within 28 days before or after each planned study vaccine administration; licensed inactivated, subunit, or conjugate vaccines within 14 days before or after each planned study vaccine administration

Treatment and study plan

Ad26.ZIKV.001 5*10^10 vp

Biological

Participants will receive Ad26.ZIKV.001 at a dose of 5*10^10 vp via IM route.

Other names: JNJ-66684657

Ad26.ZIKV.001 1*10^11 vp

Biological

Participants will receive Ad26.ZIKV.001 at a dose of 1*10^11 vp via IM route.

Other names: JNJ-66684657

Placebo

Biological

Participants will receive placebo via IM route.

Primary outcomes

  1. Number of Participants with Solicited Injection Site (Local) Adverse Events (AEs)

    Time frame: 7 days post vaccination on Day 1 (Day 1 up to Day 8)

    Number of participants with solicited injection site (local) AEs will be evaluated. Solicited local AEs including pain, erythema, and induration at the study vaccine injection site, will be noted in the participant diary from Day 1 to Day 8. Local AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).

  2. Number of Participants with Solicited Injection Site (Local) Adverse Events (AEs)

    Time frame: 7 days post vaccination on Day 57 (Day 57 up to Day 64)

    Number of participants with solicited injection site (local) AEs will be evaluated. Solicited local AEs including pain, erythema, and induration at the study vaccine injection site, will be noted in the participant diary from Day 57 to Day 64. Local AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).

  3. Number of Participants with Solicited Systemic AEs

    Time frame: 7 days post vaccination on Day 1 (Day 1 up to Day 8)

    Number of participants with solicited systemic AEs will be evaluated. Following solicited systemic AEs: fever, chills, headache, fatigue, nausea, myalgia, and arthralgia, will be noted in the participant diary from Day 1 to Day 8. Systemic AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).

  4. Number of Participants with Solicited Systemic AEs

    Time frame: 7 days post vaccination on Day 57 (Day 57 up to Day 64)

    Number of participants with solicited systemic AEs will be evaluated. Following solicited systemic AEs: fever, chills, headache, fatigue, nausea, myalgia, and arthralgia, will be noted in the participant diary from Day 1 to Day 8. Systemic AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).

  5. Number of Participants with Unsolicited AEs

    Time frame: 28 days post vaccination on Day 1 (Day 1 up to Day 29)

    Number of participants with unsolicited AEs will be evaluated. Unsolicited AEs will include all AEs for which the participant is not specifically questioned in the participant diary. Unsolicited AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).

  6. Number of Participants with Unsolicited AEs

    Time frame: 28 days post vaccination on Day 57 (Day 57 up to Day 85)

    Number of participants with unsolicited AEs will be evaluated. Unsolicited AEs will include all AEs for which the participant is not specifically questioned in the participant diary. Unsolicited AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).

  7. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: First vaccination to the end of the study (approximately up to 12 months)

    Number of participants with SAEs will be evaluated. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant or may require medical or surgical intervention to prevent one of the outcomes listed above.

  8. Number of Participants with Immediate Reportable Events (IREs)

    Time frame: First vaccination to the end of the study (approximately up to 12 months)

    Number of Participants with IREs will be evaluated. Any events of neuroimmunologic significance will be categorized as IREs.

Secondary outcomes

  1. Neutralizing Antibodies to the Vaccine Strain (or Other Strain)

    Time frame: Days 1, 8, 15, 29, 57, 64, 71, 85, 239, and 365

    Zika virus (ZIKV) neutralizing titers of the vaccine-induced immune response will be assessed using a virus neutralization assay (VNA).

Sponsors and collaborators

Lead sponsor

Janssen Vaccines & Prevention B.V.

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, First-in-Human Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Nov 29, 2017
Registry last updated
Oct 15, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.